Azurity Pharmaceuticals, Inc. Announces the Availability of BRYNOVIN™ (sitagliptin), the First and Only Oral Liquid Sitagliptin
BRYNOVIN, which was approved by the U.S. Food and Drug Administration (FDA) in January 2025, is the first and only oral liquid sitagliptin for the management of type 2 diabetes mellitus in adults in conjunction with diet and exercise.1
"BRYNOVIN demonstrates our commitment to breaking down barriers to patient care by providing sitagliptin in an oral liquid solution for adult patients with T2DM that may have difficulty swallowing pills or may have needle fear that affects treatment adherence," said Ron Scarboro, CEO at Azurity Pharmaceuticals. "Building on our longstanding legacy in dose form innovations, we continue to rapidly grow our capabilities in this space and deliver on our purpose to serve overlooked patients."
With more than 38 million Americans living with diabetes2, and 90-95% of them diagnosed with type 2 diabetes, there remains a significant need for alternative treatment options3. For many, especially older adults and those in long-term care facilities, swallowing pills is a daily challenge that may lead to poor adherence and compromised outcomes4,5.
BRYNOVIN provides effective HbA1c control as an adjunct to diet and exercise when used as monotherapy or in combination with other antihyperglycemic agents in adults with type 2 diabetes mellitus. The recommended dose of BRYNOVIN is 100 mg (25 mg/mL), administered as 4 mL once daily. BRYNOVIN is not recommended in patients with type 1 diabetes and has not been studied in patients with a history of pancreatitis. For full prescribing information, please visit brynovin.com.
1. U.S Food and Drug Administration Orange Book. Accessed July 21, 2025. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm2. Centers for Disease Control and Prevention (CDC). Type 2 Diabetes. Accessed July 17, 2025 https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html3. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report 2024. https:// www.cdc.gov/diabetes/php/data-research/methods.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/data/statistics-report4. Wittenberg E, et al. "Medication Adherence in Older Adults: A Qualitative Study." Patient Preference and Adherence. 2019;13:1443–1450.5. Schiele J et al "Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms" Eur J Clinical Pharmacol (2013) 69:937-948
About Azurity Pharmaceuticals:Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people. For more information, including prescribing information, visit www.azurity.com.
©2025 Azurity Pharmaceuticals, Inc.
PP-BRN-US-0029
View original content to download multimedia:https://www.prnewswire.com/news-releases/azurity-pharmaceuticals-inc-announces-the-availability-of-brynovin-sitagliptin-the-first-and-only-oral-liquid-sitagliptin-302519017.html
SOURCE Azurity Pharmaceuticals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
‘Zombie' rabbits with black horns and mouth tentacles are invading Colorado backyards
What the heck is that?! Rabbits in Colorado are causing alarm among residents and looking more like creatures from nightmares and not fuzzy and cuddly friends. Rabbits in Fort Collins, Colorado, are being spotted with eerie black-colored growths resembling tentacles or horns protruding from their heads. 9NEWS Northern Colorado reporter Amanda Gilbert captured a photo of one not-so-cute rabbit with the growth on its head, which resident Susan Mansfield said looked like 'black quills or black toothpicks sticking out all around his or her mouth.' 'I thought he would die off during the winter, but he didn't. He came back a second year, and it grew,' Mansfield added. Photos of another rabbit, whose growths have almost completely covered its face, have also gone viral on Reddit. Colorado Parks and Wildlife officials have identified the cause as shope papillomavirus, a rabbit-only virus with no cure that produces wart-like tumours known as papillomas, particularly around the face and head of cottontail rabbits, 9NEWS reports. The virus only spreads among rabbits, primarily by biting insects like fleas and ticks during warmer months. A relative of human papillomavirus, SPV is not harmful to humans, pets or other wildlife, and usually doesn't hurt the rabbit unless it affects the eyes or mouth, officials said. Officials advise residents to avoid approaching or touching affected rabbits. Most wild rabbits manage well, as the growths often disappear on their own. The rabbits' eerie look has gone viral, with comparisons to 'zombies,' 'aliens, and 'Frankenstein bunnies.' Their antler-like growths may have inspired the North American jackalope legend, some researchers and folklorists say. 'Wow, I kinda feel bad for them,' one person commented on an Instagram post of the affected animals. 'One time I need this to be AI,' another joked. 'Zombies are on the rise,' someone else added on Facebook. 'The rabbit escaped from 'Monty Python and The Holy Grail,'' another person referenced the cult-classic movie's killer rabbit.
Yahoo
23 minutes ago
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT
Bioventus Inc. (NASDAQ:BVS) is one of the . On August 7, Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Bioventus Inc. (NASDAQ:BVS) and set a price target of $15.00. A doctor repairing a foot and ankle injury using the latest sports medicine techniques. The analyst gave the rating after Bioventus Inc. (NASDAQ:BVS) reported its fiscal Q2 results on August 6, with reported revenue of $147.7 million declining 2.4% and organic revenue advancing 6.2%. Diluted earnings per share for Q2 was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period. Bioventus Inc. (NASDAQ:BVS) also reported cash from operations of $25.9 million and non-GAAP earnings of $0.21 per share. Bioventus Inc. (NASDAQ:BVS) is a medical technology company that develops and commercializes proprietary orthobiologic products to treat musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. While we acknowledge the potential of BVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
24 minutes ago
- The Hill
FDA may pull authorization for Pfizer COVID shot for kids under 5
The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer's COVID-19 vaccine for healthy children under 5 years old, the company confirmed Wednesday. The move would add another barrier for parents who want to vaccinate healthy children, as shots from Moderna and Novavax were approved for more limited populations. In May, Health and Human Services Secretary Robert F. Kennedy Jr. said that the Centers for Disease Control and Prevention (CDC) would no longer recommend COVID-19 vaccines for healthy children or pregnant women. The CDC then updated its immunization schedule to reflect that children with no underlying health condition 'may receive' COVID-19 vaccines after consulting with a health care provider — what's known as 'shared decision-making.' If FDA pulls its emergency use authorization, Pfizer's vaccine would no longer be available to any children younger than 5. Right now, Moderna and Novavax shots could be administered 'off label' to healthy children. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' a Pfizer spokesman told The Hill. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine which continues to demonstrate a favorable profile,' the company added. The Guardian first reported on the FDA's potential move. In a statement to The Hill, HHS said it wouldn't comment on potential changes. 'The COVID-19 pandemic ended with the expiration of the federal public health emergency in May 2023. We do not comment on potential, future regulatory changes. Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation,' HHS spokesman Andrew Nixon said. Pfizer has had full FDA approval for its COVID-19 vaccine for individuals age 12 and older since 2022.
